Edition:
United States

Biotechnology & Medical Research

Page 1

Mesoblast says qtrly loss attributable $9.8 mln

Wednesday, 24 May 2017 07:09pm EDT

May 25 (Reuters) - Mesoblast Ltd ::Qtrly loss attributable to owners of Mesoblast limited $9.8 million versus loss of $16.9 million.Q3 revenue $901,000 versus $4.1 million."There is uncertainty related to the group’s ability to partner programs and raise capital at terms to meet the group’s requirements"."Uncertain related to group’s ability to sustainably implement planned cost reductions and defer programs on timely basis while achieving expected outcomes".

Oncolytics Biotech prices public offering of units

Wednesday, 24 May 2017 10:39am EDT

May 24 (Reuters) - Oncolytics Biotech Inc : :Oncolytics Biotech® prices public offering of units.Oncolytics Biotech Inc says public offering of 14.3 million units priced at C$0.70/unit.

Actinium Pharmaceuticals granted orphan designation from the European medicines agency for Actimab-A

Wednesday, 24 May 2017 09:23am EDT

May 24 (Reuters) - Actinium Pharmaceuticals Inc : :Actinium Pharmaceuticals granted orphan designation from the european medicines agency for Actimab-A.Actinium Pharmaceuticals Inc - Actimab-A is currently in a multi-center phase 2 clinical trial.

Alnylam Pharmaceuticals prices public offering of common stock

Wednesday, 24 May 2017 09:00am EDT

May 24 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam Pharmaceuticals prices public offering of common stock.Says public offering of 5.00 million common shares priced at $71.87 per share.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary